{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:19:07Z","timestamp":1792603147060,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010226","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T00:00:00Z","timestamp":1389398400000}}],"reference-count":92,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010226.pub2","type":"journal-article","created":{"date-parts":[[2014,1,11]],"date-time":"2014-01-11T18:37:18Z","timestamp":1389465438000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Trifluoperazine versus placebo for schizophrenia"],"prefix":"10.1002","volume":"2014","author":[{"given":"Kai","family":"Koch","sequence":"first","affiliation":[{"name":"The University of Nottingham; School of Medicine; University Park Queens Medical Centre Nottingham Nottinghamshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Mansi","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euan","family":"Haynes","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sampson","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek A","family":"Furtado","sequence":"additional","affiliation":[{"name":"Institute of Mental Health; Forensic Psychiatry; The University of Nottingham Nottingham Nottinghamshire UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,11]]},"reference":[{"key":"10.1002\/14651858.CD010226.pub2-BIB0001|cit1","first-page":"674","article-title":"A controlled evaluation of butaperazine in chronic schizophrenic patients","volume":"25","author":"Bishop","year":"1964","journal-title":"Diseases of the Nervous System"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD010226.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/j.1552-4604.1975.tb01450.x","article-title":"Loxapine in newly admitted chronic schizophrenic patients","volume":"15","author":"Clark","year":"1975","journal-title":"Journal of Clinical Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD010226.pub2-BIB0003|cit3","first-page":"696","article-title":"A double-blind comparison of once-a-day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients","volume":"16","author":"Gross","year":"1974","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00005053-196205000-00008","article-title":"Efficacy of trifluoperazine on withdrawal in chronic schizophrenia","volume":"134","author":"Gwynne","year":"1962","journal-title":"Journal of Nervous and Mental Disease"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/070674376400900404","article-title":"Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients","volume":"60","author":"Marjerrison","year":"1964","journal-title":"Canadian Psychiatric Association Journal"},{"issue":"1 January","key":"10.1002\/14651858.CD010226.pub2-BIB0006|cit6","first-page":"17","article-title":"A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients","volume":"14","author":"Menon","year":"1972","journal-title":"Current Therapeutic Research"},{"issue":"1","key":"10.1002\/14651858.CD010226.pub2-BIB0007|cit7","first-page":"53","article-title":"Pimozide and social rehabilitation of chronic schizophrenic patients","volume":"61","author":"Pinard","year":"1972","journal-title":"L'Encephale"},{"issue":"3","key":"10.1002\/14651858.CD010226.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1176\/ajp.126.3.305","article-title":"High dose trifluoperazine therapy in chronic schizophrenia","volume":"126","author":"Prien","year":"1969","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0009|cit9","first-page":"265","article-title":"Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo)","volume":"27","author":"Reardon","year":"1966","journal-title":"Diseases of the Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD010226.pub2-BIB0010|cit10","first-page":"151","article-title":"A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic hospitalized, schizophrenic patients","volume":"22","author":"Schiele","year":"1961","journal-title":"Journal of Clinical and Experimental Psychopathology"},{"issue":"3","key":"10.1002\/14651858.CD010226.pub2-BIB0011|cit11","first-page":"26","article-title":"The treatment of schizophrenia with long-acting oral neuroleptics: a six-month double-blind investigation of penfluridol versus trifluoperazine","volume":"13","author":"Abuzzahab","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1176\/ajp.118.4.347","article-title":"A \"double-blind\" study comparing RO 4-0403, trifluoperazine and a placebo in chronically ill mental patients","volume":"118","author":"Barron","year":"1961","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/ajp.116.9.838","article-title":"Efficacy of trifluoperazine in chronic mental illness","volume":"116","author":"Cahan","year":"1960","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/070674376200700403","article-title":"Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients","volume":"7","author":"Coons","year":"1962","journal-title":"Canadian Psychiatric Association Journal"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1192\/bjp.109.461.510","article-title":"A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment","volume":"109","author":"Hamilton","year":"1963","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010226.pub2-BIB0016|cit16","first-page":"298","article-title":"The clinical effects of intramuscular thiothixene and trifluoperazine in chronic schizophrenia: a comparative study","volume":"13","author":"Holden","year":"1971","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"505","key":"10.1002\/14651858.CD010226.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1192\/bjp.113.505.1419","article-title":"A comparison of the effects of oxypertine and trifluoperazine in withdrawn schizophrenics","volume":"113","author":"Hunt","year":"1967","journal-title":"British Journal of Psychiatry"},{"issue":"775","key":"10.1002\/14651858.CD010226.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/bmj.3.5775.599","article-title":"Trial of maintenance therapy in schizophrenia","volume":"3","author":"Leff","year":"1971","journal-title":"British Medical Journal"},{"issue":"5885","key":"10.1002\/14651858.CD010226.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/bmj.4.5885.156","article-title":"Influence of selection of patients on results of clinical trials","volume":"4","author":"Leff","year":"1973","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1192\/bjp.104.437.1195","article-title":"Stelazine (trifluoperazine). A preliminary report on a clinical trial","volume":"104","author":"Madgwick","year":"1958","journal-title":"Journal of Mental Science"},{"issue":"11","key":"10.1002\/14651858.CD010226.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1176\/ajp.124.11.1585","article-title":"A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia","volume":"124","author":"Morton","year":"1968","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1192\/bjp.107.447.250","article-title":"Trifluoperazine (stelazine). A controlled clinical trial in chronic schizophrenia","volume":"107","author":"Stanley","year":"1961","journal-title":"Journal of Mental Science"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1192\/bjp.106.444.1008","article-title":"Clinical trial of 'stelazine' on apathetic chronic schizophrenics","volume":"106","author":"Weckowicz","year":"1960","journal-title":"Journal of Mental Science"},{"issue":"1","key":"10.1002\/14651858.CD010226.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.5694\/j.1326-5377.1961.tb69141.x","article-title":"A terminal double-blind trial of tri-fluoperazine (\"stelazine\") in chronic schizophrenia","volume":"48","author":"Weston","year":"1961","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0025|cit25","doi-asserted-by":"crossref","unstructured":"Ortega-Soto HA Brunner E Apiquian R de la Torre MP Ulloa RE Typical antipsychotics: the threshold doses strategy Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia 1996","DOI":"10.1016\/0924-977X(96)88238-1"},{"issue":"7066","key":"10.1002\/14651858.CD010226.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0027|cit27","volume-title":"Handbook of Psychiatric Drug Therapy. USA","author":"Arana","year":"2000"},{"issue":"1","key":"10.1002\/14651858.CD010226.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1600-0447.1988.tb05080.x","article-title":"Clinical symptomatology and drug compliance in schizophrenic patients","volume":"77","author":"Bartko","year":"1988","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0029|cit29","volume-title":"Psychotropic Drug Directory. USA","author":"Bazire","year":"2000"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0031|cit31","unstructured":"BMJ Group and Pharmaceautical Press British National Formulary No. 63. Antipsychotic drugs BNF 2012"},{"issue":"4","key":"10.1002\/14651858.CD010226.pub2-BIB0032|cit32","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0033|cit33","unstructured":"Cost-Effectiveness Analysis Registry (CEA) https:\/\/research.tufts-nemc.org\/cear4\/ accessed 11\/09\/13"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/bjp.bp.106.028654","article-title":"Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy","volume":"191","author":"Davies","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0035|cit35","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"6","key":"10.1002\/14651858.CD010226.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"3 August","key":"10.1002\/14651858.CD010226.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010226.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2 Spring","key":"10.1002\/14651858.CD010226.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","article-title":"Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria","volume":"21","author":"Evers","year":"2005","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1037\/h0044648","article-title":"A scale for measuring minimal social behaviour","volume":"21","author":"Farina","year":"1957","journal-title":"Journal of Consultant Psychology"},{"issue":"3","key":"10.1002\/14651858.CD010226.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7175\/fe.v6i3.832","article-title":"Treatment of psychotic disorders with olanzapine, risperidone and typical neuroleptics: a comparative cost-effectiveness evaluation in a local psychiatric setting","volume":"6","author":"Filippelli","year":"2005","journal-title":"Farmeconomia e Percorsi Terapeutici"},{"issue":"7","key":"10.1002\/14651858.CD010226.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD010226.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0149-2918(99)80028-9","article-title":"Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center","volume":"21","author":"Galvin","year":"1999","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/875512250101700606","article-title":"Economic outcomes of risperidone in comparison to typical neuroleptic agents for treatment-resistant psychosis: a community-based study","volume":"17","author":"Ghaemi","year":"2001","journal-title":"Journal of Pharmacy Technology"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1176\/ajp.110.5.334","article-title":"Quantification of the severity of overt psychotic symptoms","volume":"110","author":"Goodrich","year":"1953","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0049|cit49","first-page":"12","article-title":"Clinical Global Impressions","volume-title":"Manual for the ECDEU Assessment Battery","author":"Guy","year":"1970"},{"issue":"13","key":"10.1002\/14651858.CD010226.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14656566.7.13.1749","article-title":"Cost-effectiveness of atypical antipsychotic medications versus conventional medication","volume":"7","author":"Hanrahan","year":"2006","journal-title":"Expert Opinion in Pharmacotherapy"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/00223980.1940.9917000","article-title":"A multiphasic personality schedule (Minnesota): I. Construction of the schedule","volume":"10","author":"Hathaway","year":"1940","journal-title":"Journal of Psychology"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0052|cit52","unstructured":"Health Economic Evaluation Database (HEED) Online ISBN: 9780470510933 10.1002\/9780470510933"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0053|cit53","unstructured":"Hospital Episode Statistics, Admitted Patient Care - England 2011-12: Main Specialties (.xls) http:\/\/www.hscic.gov.uk\/searchcatalogue?productid=9161&q=title%3a%22hospital+episode+statistics%22&sort=Relevance&size=10&page=1#top (accessed May 2013)"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0055|cit55","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0056|cit56","volume-title":"Pocket Handbook of Clinical Psychiatry. USA","author":"Kaplan","year":"1998"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0057|cit57","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"4","key":"10.1002\/14651858.CD010226.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00019053-200826040-00006","article-title":"Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study","volume":"26","author":"Knapp","year":"2008","journal-title":"PharmacoEconomics"},{"issue":"7","key":"10.1002\/14651858.CD010226.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009935","article-title":"Quetiapine versus placebo for schizophrenia","author":"Lankappa","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"May 10","key":"10.1002\/14651858.CD010226.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","article-title":"New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis","volume":"361","author":"Leucht","year":"2003","journal-title":"Lancet"},{"issue":"2-3","key":"10.1002\/14651858.CD010226.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010226.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD010226.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/070674379804300608","article-title":"Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms","volume":"43","author":"Lewis","year":"1998","journal-title":"Canadian Journal of Psychiatry"},{"issue":"17","key":"10.1002\/14651858.CD010226.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10170","article-title":"Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment","volume":"10","author":"Lewis","year":"2006","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/1097-4679(196007)16:3<241::AID-JCLP2270160305>3.0.CO;2-F","article-title":"The psychotic reaction profile","volume":"16","author":"Lorr","year":"1960","journal-title":"Journal of Clinical Psychology"},{"issue":"1","key":"10.1002\/14651858.CD010226.pub2-BIB0067|cit67","first-page":"23","article-title":"Cost of schizophrenia in England","volume":"10","author":"Mangalore","year":"2007","journal-title":"Journal of Mental Health Policy and Economics"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010226.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eurpsy.2005.09.009","article-title":"Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia","volume":"21","author":"Martin","year":"2006","journal-title":"European Psychiatry"},{"issue":"Jan","key":"10.1002\/14651858.CD010226.pub2-BIB0070|cit70","first-page":"1","article-title":"Massive chlorpromazine therapy: the nature of behavioural changes","volume":"33","author":"Mendelsohn","year":"1959","journal-title":"Psychiatric Quarterly"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0071|cit71","unstructured":"Mental Health Care: reliable and up-to-date information about psychosis for family members and friends http:\/\/www.mentalhealthcare.org.uk\/pharmacist_answers_september_august_2011 accessed September 2013"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285(12)","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD010226.pub2-BIB0073|cit73","first-page":"108","article-title":"Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics","volume":"2","author":"Mould","year":"2009","journal-title":"Revista de Psiquiatr\u00ed\u0301a y Salud Mental"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0074|cit74","unstructured":"NICE Schizophrenia: Core interventions in the treatment and management in adults in primary and secondary care - National Clinical Guideline Number 82 http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG82FullGuideline.pdf 2010 4 41"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0076|cit76","unstructured":"PJ Online: Do you accept that medicine shortages have not harmed patients? http:\/\/www.pjonline.com\/poll\/do_you_accept_that_medicine_shortages_have_not_harmed_patients Accessed September 2013"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0077|cit77","unstructured":"Compiled by Lesley Curtis Unit costs of health and social care 2012 http:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/2012\/ (accessed May 2013) 2012 47"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0078|cit78","unstructured":"Royal College of Psychiatrists Antipsychotics RCPSYCH 2009"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0079|cit79","unstructured":"Royal College of Psychiatrists Schizophrenia RCPSYCH 2010"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0080|cit80","unstructured":"Royal College of Psychiatrists Schizophrenia RCPSYCH 2011"},{"issue":"5","key":"10.1002\/14651858.CD010226.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"0413","DOI":"10.1371\/journal.pmed.0020141","article-title":"Systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Medicine"},{"issue":"10","key":"10.1002\/14651858.CD010226.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","article-title":"A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?","volume":"64","author":"Saha","year":"2007","journal-title":"Archives of General Psychiarty"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"issue":"2","key":"10.1002\/14651858.CD010226.pub2-BIB0084|cit84","first-page":"89","article-title":"Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care","volume":"11","author":"Stargardt","year":"2008","journal-title":"Journal of Mental Health Policy and Economics"},{"issue":"2","key":"10.1002\/14651858.CD010226.pub2-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007815","article-title":"Quetiapine versus typical antipsychotic medications for schizophrenia","author":"Suttajit","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9690","key":"10.1002\/14651858.CD010226.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with\u00a0schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010226.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"s7","DOI":"10.1136\/bmj.39034.609074.94","article-title":"Chlorpromazine: unlocking psychosis","volume":"334","author":"Turner","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD010226.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0089|cit89","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-349-18800-0_1","article-title":"Health economics: the cheerful face of dismal science?","volume-title":"Health and economics","author":"Williams","year":"1987"},{"key":"10.1002\/14651858.CD010226.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1192\/bjp.107.450.862","article-title":"A simple and reliable subclassification of chronic schizophrenia","volume":"107","author":"Wing","year":"1961","journal-title":"Journal of Mental Science"},{"issue":"7","key":"10.1002\/14651858.CD010226.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD010226.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003545","article-title":"Trifluoperazine for schizophrenia","author":"Marques","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010226.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T13:43:00Z","timestamp":1720532580000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010226.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,11]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010226.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,11]]}}}